• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CalAmp Appoints Chris Adams as President and Chief Executive Officer

    1/8/24 6:30:00 AM ET
    $CAMP
    Get the next $CAMP alert in real time by email

    IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024.

    Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi.

    "After a comprehensive search process, we are pleased to welcome Chris as CalAmp's new President and CEO. His deep experience in semiconductor, hardware, and software solutions across several market segments – most recently in the automotive segment – makes him an excellent choice to lead CalAmp through the next phase of its transformation. We have great confidence in his ability to drive the company to create greater value for customers and investors," said Henry Maier, Chairman of the Board at CalAmp.

    Adams started his career in engineering and engineering leadership and has served in general management roles for more than 20 years. Prior to his current role at onsemi, Adams held business unit leadership roles with LSI Logic, Sony Electronics, and BAE Systems. Adams also served as President and CEO of Pixim, an imaging semiconductor company that was subsequently acquired by Sony Electronics. Adams holds a Master of Science Degree in Electrical Engineering from Stanford University.

    "I'm excited to have the opportunity to lead this exceptional organization, which has such deep expertise in the large and growing telematics industry," said Adams. "CalAmp has long been an innovator and I believe the transformation the organization has been undergoing will provide more value to customers and ultimately lasting value to investors. The organization has all the ingredients necessary to drive profitable growth and to solidify its leadership position in telematics solutions."

    Jason Cohenour, Interim CEO of CalAmp, will be working with Chris and the CalAmp management team to ensure a smooth transition of leadership responsibilities. Following the transition, Cohenour will resume his role as independent director of CalAmp's board of directors.

    About CalAmp

    CalAmp (NASDAQ:CAMP) provides flexible solutions to help organizations worldwide monitor, track and protect their vital assets. Our unique device-enabled software and cloud platform enables commercial and government organizations worldwide to improve efficiency, safety, visibility and compliance while accommodating the unique ways they do business. With over 10 million active edge devices and 275+ approved or pending patents, CalAmp is the telematics leader organizations turn to for innovation and dependability. For more information, visit calamp.com, or LinkedIn, Twitter, YouTube or CalAmp Blog.

    CalAmp, LoJack, TRACKER, Here Comes The Bus, Bus Guardian, CalAmp Vision, CrashBoxx and associated logos are among the trademarks of CalAmp and/or its affiliates in the United States, certain other countries and/or the EU. Spireon acquired the LoJack® U.S. Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada. Any other trademarks or trade names mentioned are the property of their respective owners.

    Forward-Looking Statements

    This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning CalAmp. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, (ii) our competitive position and opportunities, (iii) our comprehensive review of strategic alternatives focused on enhancing shareholder value, and (iv) other statements identified by words such as such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict", "project", "aim", "goal", and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, current market trends and market conditions, and involve risks and uncertainties, many of which are outside of our control, and which may cause actual results to differ materially from those contained in forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect future results include any risks associated with global economic conditions and concerns; the outcome of our comprehensive review of strategic alternatives, including the availability of any strategic alternatives that are worthwhile to pursue; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic; global component shortages due to supply chain constraints, such as those caused by the COVID-19 pandemic; disruptions in sales, operations, relationships with customers, suppliers, employees; our ability to successfully and timely accomplish our transformation to a SaaS solutions provider; our transition out of the automotive vehicle financing business; competitive pressures; pricing declines; demand for our telematics products; rates of growth in our target markets; prolonged disruptions of our contract manufacturers' facilities or other significant operations; force majeure or force-majeure-like events at our contract manufacturers' facilities including component shortages; the ongoing diversification of our global supply chain; our dependence on outsourced service providers for certain key business services and their ability to execute to our requirements; our ability to improve gross margin; cost-containment measures; legislative, trade, tariff, and regulatory actions; integration, unexpected charges or expenses in connection with acquisitions; the impact of legal proceedings and compliance risks; the impact on our business and reputation from information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data protection; our ability to protect our intellectual property and the unpredictability of any associated litigation expenses; any expenses or reputational damage associated with resolving customer product and warranty and indemnification claims; our ability to sell to new types of customers and to keep pace with technological advances; market acceptance of the end products into which our products are designed; and other events and trends on a national, regional and global scale, including those of a political, economic, business, competitive, and regulatory nature. More information on these risks and other potential factors that could affect our financial results is included in our filings with the U.S. Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings, which you may obtain for free at the SEC's website at http://www.sec.gov. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, which speak as of their respective dates except as required by law.

    CalAmp Investor

    Contact:
    CalAmp Media

    Contact:
    Jikun KimMark Gaydos
    SVP & CFOChief Marketing & Product Officer
    [email protected][email protected]



    Primary Logo

    Get the next $CAMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    12/22/2021$14.00 → $10.00Buy → Hold
    Craig-Hallum
    9/24/2021$16.00 → $14.00Buy
    Craig Hallum
    6/25/2021$19.00 → $18.50Buy
    Roth Capital
    More analyst ratings

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP

    $CAMP
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP
    • SEC Form 10-Q filed by CAMP4 Therapeutics Corporation

      10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:26:54 PM ET
      $CAMP
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:20:45 PM ET
      $CAMP

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP
    • CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three

      4/28/25 4:30:00 PM ET
      $CAMP
    • CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics de

      3/27/25 4:05:00 PM ET
      $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Bumcrot David

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:09:40 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Medical Officer Maricich Yuri

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:08:11 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Financial Officer Gold Kelly

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:07:07 PM ET
      $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    See more

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CAMP
    Financials

    Live finance-specific insights

    See more
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalAmp Appoints Chris Adams as President and Chief Executive Officer

      IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

      1/8/24 6:30:00 AM ET
      $CAMP
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP
    • JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

      JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

      11/5/24 6:14:20 AM ET
      $CAMP
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP
    • Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 5:05:20 PM ET
      $CAMP
    • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

      IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

      1/9/24 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

      IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

      12/26/23 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

      IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

      12/18/23 4:31:00 PM ET
      $CAMP